{"id":798944,"date":"2026-03-30T11:09:02","date_gmt":"2026-03-30T11:09:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=798944"},"modified":"2026-03-30T11:09:02","modified_gmt":"2026-03-30T11:09:02","slug":"stocks-under-010-itrm-amlm-bfrg-qncx-admq-march-madness-watch","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/stocks-under-010-itrm-amlm-bfrg-qncx-admq-march-madness-watch_798944.html","title":{"rendered":"Stocks Under $0.10: ITRM, AMLM, BFRG, QNCX, ADMQ March Madness Watch"},"content":{"rendered":"
\"Stocks<\/a><\/div>\n

A group of sub-$0.10 and low-priced small-cap stocks<\/strong> is drawing increased attention as investors rotate into high-beta, low-float names<\/strong> across biotechnology, artificial intelligence, and critical minerals<\/strong>. With volatility rising and capital flowing into speculative growth themes, several companies are emerging on trader and investor watchlists.<\/p>\n

Biotech Momentum: Iterum Therapeutics (NASDAQ: ITRM) <\/strong><\/p>\n

Biotech names ITRM<\/strong> have seen increased activity, moving sharply in pre-market trading<\/strong> as investors target rare-disease and orphan-drug opportunities<\/strong>. The company’s focus on late-infantile neuronal ceroid lipofuscinosis (LINCL)<\/strong> and related pediatric neurodegenerative disorders positions it within a niche where limited treatment options and orphan-drug economics<\/strong> can drive outsized valuation shifts on clinical progress.<\/p>\n

Critical Minerals & Supply Chain Theme: American Lithium Minerals (OTC: AMLM)<\/strong><\/p>\n

AMLM continues to gain traction as a diversified critical minerals explorer<\/strong> with exposure to lithium, gold, silver, copper, and rare earth elements<\/strong>. The company’s Nevada lithium asset<\/strong> has recently been validated through independent analysis, while its broader portfolio spans Quebec polymetallic projects, Chile copper and silver assets, and international gold exposure<\/strong>.<\/p>\n

With increasing focus on U.S. supply-chain security, EV batteries, AI infrastructure, and electrification metals<\/strong>, AMLM’s multi-commodity approach helps reduce risk while maintaining upside exposure<\/strong>. Rising trading activity and a low public float structure<\/strong> have also placed the stock on momentum watchlists.<\/p>\n

AI Meets Drug Discovery: BullFrog AI Holdings (NASDAQ: BFRG)<\/strong><\/p>\n

BullFrog AI<\/strong> is gaining visibility after announcing a commercial agreement with a top 5 global pharmaceutical company<\/strong> to apply its bfLEAP® AI platform<\/strong> to identify and prioritize drug targets in major depressive disorder (MDD)<\/strong>. The deal includes exclusive access to a target candidate<\/strong>, highlighting the growing role of AI and machine learning in accelerating drug discovery<\/strong>.<\/p>\n

Balance Sheet Reset: Quince Therapeutics (NASDAQ: QNCX)<\/strong><\/p>\n

Quince Therapeutics<\/strong> recently announced the settlement of its European Investment Bank loan<\/strong> for $5.5 million, removing a key financial overhang. Balance sheet improvements are often closely watched in small-cap biotech, particularly as companies reposition for clinical advancement and strategic flexibility<\/strong>.<\/p>\n

Earnings Catalyst Ahead: ADM Endeavors (OTCQB: ADMQ)<\/strong><\/p>\n

ADM Endeavors<\/strong> remains on watch ahead of its March 2026 earnings report<\/strong>, following its expansion into a 100,000-square-foot $13M production facility<\/strong> designed to significantly increase output capacity. Growth in manufacturing<\/strong> apparel and custom promotional products<\/strong> continues to support the company’s expansion strategy.<\/p>\n

The Bigger Picture<\/strong><\/p>\n

Across sectors, a common theme is emerging:low-priced, low-float stocks with defined catalysts are regaining attention<\/strong>.<\/p>\n